IncellDx Gains CE-IVD Mark for ‘Long COVID’ Diagnostic

September 2, 2022

San Carlos, Calif.-based IncellDx’s incellKINE in vitro diagnostic test for Long COVID has gained Europe’s CE-IVD mark.

The CE-IVD certification is the first ever for a diagnostic that can identify patients with the condition. The blood test is used to diagnose patients with “post-acute sequelae” following a COVID-19 infection.

In a validation study, the blood test showed more than 90 percent accuracy across COVID strains, the company said.

IncellDx said it plans to launch the test in Europe this month.

View today's stories